Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study

Figures & data

Figure 1. Location of selected communities in Shanghai.

Table 1. Demographic characteristics of participants in the study.

Characteristics	With all 6 visits N (%)	Missing or withdrawal N (%)	χ^2	P
Age (years)
60–69	366 (70.79)	369 (70.02)	1.731	0.421
70–79	141 (27.27)	141 (26.76)
≥80	10 (1.93)	17 (3.23)
Sex
Male	243 (47.00)	231 (43.83)	1.057	0.304
Female	274 (53.00)	296 (56.17)
District#
Urban	106 (20.50)	206 (39.09)	153.66	<0.001
Suburban near urban	271 (52.41)	85 (16.13)
Suburban far from urban	140 (27.08)	236 (44.78)
Smoking
Often*	94 (18.18）	48 (9.11）	55.092	<0.001
Occasionally^§	6 (1.16）	9 (1.71)
Never	391 (75.63)	375 (71.16)
Unknow	26 (5.03)	95 (18.03)
Drinking
Often*	54 (10.44)	39 (7.40)	43.656	<0.001
Occasionally^§	21 (4.06)	31 (5.88)
Never	391 (75.63)	362 (68.69)
Unknow	26 (5.03)	95 (18.03)
Exercising
Often*	136 (26.31)	81 (15.37)	58.811	<0.001
Occasionally^§	121 (23.40)	91 (17.27)
Never	234 (45.26)	260 (49.34)
Unknow	26 (5.03)	95 (18.03)
Chronic pulmonary diseases
Yes	19 (3.68)	11 (2.09)	44.956	<0.001
No	473 (91.49)	422 (80.08)
Unknown	25 (4.84)	94 (17.84)
Chronic underlying diseases
Yes	242 (46.81)	204 (38.71)	44.075	<0.001
No	250 (48.36)	229 (43.45)
Unknown	25 (4.84)	94 (17.84)
Total	517 (49.52)	527 (50.48)

^#Urban districts include Huangpu and Yangpu districts, and Suburban districts include Baoshan, Jiading, Songjiang, and Qingpu districts. * Often referred to 3–5 times/week. ^§ Occasionally referred to 1–2 times/week.

Figure 2. GMC of 23 serotypes before vaccination and after PPV23 vaccination within 5 years.

Table 2. The baseline antibody levels between participants who completed all visits and partial visits.

	With all 6 visits (N = 517)		Missing or withdrawal (N = 527)
Serotype	GMC of antibody (µg/mL)	95% confidence interval	GMC of antibody (µg/mL)	95% confidence interval	t	P
1	8.64	8.23–9.08	8.64	8.23–9.08	0.000	1.000
2	8.06	7.68–8.46	8.08	7.72–8.46	0.088	0.930
3	3.45	3.30–3.61	3.60	3.45–3.80	1.462	0.144
4	0.67	0.64–0.70	0.68	0.65–0.71	0.502	0.616
5	4.11	3.95–4.27	4.18	4.02–4.36	0.641	0.522
6B	10.35	9.89–10.82	10.40	9.94–10.89	0.170	0.865
7F	2.55	2.42–2.68	2.70	2.57–2.83	1.598	0.110
8	4.23	4.06–4.4	4.28	4.10–4.46	0.420	0.674
9N	4.07	3.89–4.27	4.46	4.25–4.68	2.668	0.008*
9 V	3.04	2.87–3.22	3.09	2.92–3.26	0.349	0.727
10A	8.55	8.2–8.91	8.56	8.21–8.93	0.063	0.950
11A	3.68	3.49–3.89	3.83	3.64–4.03	1.022	0.307
12F	1.87	1.79–1.95	1.87	1.80–1.95	0.080	0.936
14	27.11	25.89–28.39	26.79	25.64–27.99	−0.371	0.710
15B	9.93	9.51–10.38	10.33	9.88–10.81	1.228	0.220
17F	3.18	3.04–3.34	3.33	3.18–3.49	1.342	0.180
18C	4.57	4.36–4.79	4.81	4.58–5.05	1.457	0.146
19A	3.18	3.05–3.31	3.22	3.10–3.35	0.514	0.607
19F	6.36	6.08–6.64	6.42	6.15–6.70	0.295	0.768
20	9.81	9.29–10.35	10.68	10.13–11.26	2.221	0.027*
22F	5.12	4.91–5.34	5.29	5.08–5.52	1.122	0.262
23F	10.35	9.86–10.87	10.63	10.13–11.14	0.755	0.450
33F	9.61	9.17–10.08	10.24	9.77–10.72	1.857	0.064

*P < 0.05.

Figure 3. Fold increase in GMC of 23 serotypes from 1 to 5 years after PPV23 vaccination comparing with that before vaccination.

Figure 4. Dynamic trend of IgG GMC of 23 serotypes before and after PPV23 vaccination within 5 years.

Data availability statement

The data generated and/or analyzed during this study are available from the corresponding author on reasonable request.